
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES136
When individual endpoints were analysed the RCT256 reported: a statistically significant reduction in the risk of all-cause mortality in losartan-treated patients compared to those receiving atenolol. RR 0.61 (95% CI 0.45 to 0.84), p=0.002  a statistically significant reduction in the risk of CV death favouring the losartan group RR 0.63 (95% CI 0.42 to 0.95), p= 0.028  non-significant difference in the incidence of stroke or MI between patients treated with losartan and those treated with atenolol.

[@Whelton_2005]

